Pathological complete response and accelerated drug approval in early breast cancer
N Engl J Med
.
2012 Jun 28;366(26):2438-41.
doi: 10.1056/NEJMp1205737.
Epub 2012 May 30.
Authors
Tatiana M Prowell
1
,
Richard Pazdur
Affiliation
1
Office of Hematology Oncology Products, Food and Drug Administration, Silver Spring, MD, USA.
PMID:
22646508
DOI:
10.1056/NEJMp1205737
No abstract available
MeSH terms
Breast Neoplasms / drug therapy*
Chemotherapy, Adjuvant*
Drug Approval*
Female
Humans
Time Factors
United States
United States Food and Drug Administration